DXCM AI Stock Analysis – Buy, Hold, or Avoid?
DexCom, Inc. (DXCM)
DexCom presents a fundamentally strong long-term growth story with industry-leading margins and robust innovation, but faces near-term technical weakness and moderating growth. While valuation remains elevated, it is justified by recurring revenues and product leadership, though technicals and sentiment suggest caution for short-term traders. Investors should monitor for a confirmed trend reversal or new catalysts before increasing exposure.
Fundamentals
DexCom exhibits robust fundamental health powered by strong revenue growth and margin expansion, anchored by its market leadership in continuous glucose monitoring systems. While recent quarters show some softening in sales momentum and net income, the company sustains impressive margins and operational effectiveness, keeping its financial performance resilient despite market headwinds.
Financial Highlights
- Revenue
- Net Income
- Net Margin (%)
Revenue
15.05% YoY
Q1 2026
Net Income
89.28% YoY
Q1 2026
Net Margin
Q1 2026
Growth Metrics
Revenue Growth YoY
Latest Quarter: Q1 2026
Net Income Growth YoY
Latest Quarter: Q1 2026
Revenue Per Share Growth YoY
Latest Quarter: Q1 2026
EPS Growth YoY
Latest Quarter: Q1 2026
Book Value Per Share Growth YoY
Latest Quarter: Q1 2026
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.2B | 1.3B | 1.2B | 1.2B | 1.0B | 1.1B | 994.2M | 1.0B |
| Revenue Growth YoY | +15.05% | +13.12% | +21.64% | +15.21% | +12.49% | +7.64% | +1.97% | +15.26% |
| Net Income | 199.5M | 267.3M | 283.8M | 179.8M | 105.4M | 151.7M | 134.6M | 143.5M |
| Net Income Growth YoY | +89.28% | +76.20% | +110.85% | +25.30% | -28.01% | -40.81% | +11.52% | +23.81% |
| EPS | $0.52 | $0.69 | $0.73 | $0.46 | $0.27 | $0.39 | $0.35 | $0.36 |
| EPS Growth YoY | +92.59% | +76.92% | +108.57% | +27.78% | -28.95% | -41.79% | +12.90% | +20.00% |
Profitability Metrics
Gross Margin
TTM
Operating Margin
TTM
Net Margin
TTM
Return on Equity
TTM
Return on Assets
TTM
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 62.95% | 62.93% | 61.80% | 59.53% | 56.85% | 58.90% | 59.73% | 62.40% |
| Operating Margin | 21.42% | 25.64% | 20.05% | 18.37% | 12.91% | 16.96% | 15.29% | 15.73% |
| Net Margin | 16.74% | 21.22% | 23.47% | 15.54% | 10.17% | 13.62% | 13.54% | 14.29% |
| Return on Equity (ROE) | 6.75% | 9.73% | 10.41% | 6.99% | 4.65% | 7.21% | 6.80% | 5.89% |
| Return on Assets (ROA) | 3.05% | 4.28% | 3.84% | 2.49% | 1.59% | 2.39% | 2.16% | 2.15% |
Technical Analysis
DexCom (DXCM) is currently in a strong downtrend, trading below key moving averages with a death cross in place. Momentum indicators like RSI are neutral, but price action along with a Stage 4 declining phase signals bearish control. Key support lies near $56.11 and $53.75, with resistance levels at $63.74 and $66.11, suggesting potential bounces if these are tested or broken.
No extreme reading
Price in downtrend
Strong trend active
50 below 200 - bearish
Key Technical Values
Price with Moving Averages
50-day, 150-day and 200-day simple moving averages
Relative Strength Index
Momentum oscillator measuring speed and magnitude of price changes
RSI (14)
Earnings
DexCom exhibits robust fundamental health powered by strong revenue growth and margin expansion, anchored by its market leadership in continuous glucose monitoring systems. While recent quarters show some softening in sales momentum and net income, the company sustains impressive margins and operational effectiveness, keeping its financial performance resilient despite market headwinds.
Latest Earnings
Q1 2026 Earnings (Mar 31, 2026)
Earnings Per Share (EPS)
Actual
$0.56
Estimated
$0.47
Surprise
+$0.09
Surprise %
+19.15%
Revenue
Actual
$1.19B
Estimated
$1.17B
Surprise
+$17.22M
Surprise %
+1.47%
Historical Earnings
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share | ||||||||
| EPS (Actual) | $0.56 | $0.68 | $0.61 | $0.48 | $0.32 | $0.45 | $0.45 | $0.43 |
| EPS (Estimated) | $0.47 | $0.65 | $0.58 | $0.44 | $0.33 | $0.48 | $0.44 | $0.39 |
| EPS Surprise | +$0.09 | +$0.03 | +$0.03 | +$0.04 | -$0.01 | -$0.03 | +$0.01 | +$0.04 |
| % Diff | +19.1% | +4.6% | +5.9% | +8.2% | -2.2% | -6.1% | +2.3% | +10.3% |
| Revenue | ||||||||
| Revenue (Actual) | $1.19B | $1.26B | $1.21B | $1.16B | $1.04B | $1.11B | $994.2M | $1B |
| Revenue (Estimated) | $1.17B | $1.25B | $1.18B | $1.12B | $1.02B | $1.11B | $990.44M | $1.04B |
| Revenue Surprise | +$17.22M | +$11.33M | +$25.56M | +$32.49M | +$18.59M | +$4.35M | +$3.76M | -$32.9M |
| % Diff | +1.5% | +0.9% | +2.2% | +2.9% | +1.8% | +0.4% | +0.4% | -3.2% |
Valuation
DexCom (DXCM) presents a mixed valuation picture characterized by premium multiples relative to its medical device peers, reflecting the market's confidence in its growth prospects and product leadership. Despite recent multiple compression, DXCM enjoys strong analyst support with price targets signaling significant upside potential. However, elevated valuation ratios suggest the stock trades closer to growth expectations than current fundamentals alone might justify.
Valuation Metrics
Price to Earnings
TTM
Price to Sales
TTM
Price to Book
TTM
Enterprise Value to EBITDA
TTM
Enterprise Value to Revenue
TTM
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Price to Earnings | 30.31 | 24.00 | 23.18 | 47.59 | 63.35 | 51.18 | 49.08 | 78.01 |
| Price to Sales | 20.29 | 20.38 | 21.76 | 29.58 | 25.78 | 27.89 | 26.58 | 44.59 |
| Price to Book | 8.18 | 9.35 | 9.65 | 13.30 | 11.78 | 14.77 | 13.35 | 18.39 |
| Enterprise Value to EBITDA | 75.84 | 67.33 | 88.39 | 129.34 | 146.55 | 120.57 | 119.62 | 189.76 |
| Enterprise Value to Revenue | 20.51 | 20.75 | 22.37 | 30.81 | 27.40 | 29.67 | 28.56 | 46.23 |
Sentiment & Analyst Ratings
DexCom's market sentiment exhibits a cautiously optimistic tone driven by strong Q1 2026 earnings and promising product launches like the G7 15-day CGM system. Analysts predominantly maintain Buy or Strong Buy ratings with upside price targets suggesting significant potential appreciation. Social media and news coverage reflect a balanced but positive sentiment, with some retail investor caution due to reaffirmed guidance and geopolitical concerns.
Analyst Recommendations
Risk Assessment
Dexcom (DXCM) exhibits a solid financial position with strong liquidity and manageable leverage, supporting its operational stability in a competitive healthcare market. Despite positive earnings momentum and favorable analyst outlook, risks from slower U.S. market growth, regulatory uncertainty, and cost pressures could temper near-term growth. The company’s financial health and innovative product pipeline offer a balanced risk-return profile for investors.
Liquidity & Solvency
Current Ratio
Latest Quarter: Q1 2026
Quick Ratio
Latest Quarter: Q1 2026
Debt-to-Equity
Latest Quarter: Q1 2026
Debt-to-Assets
Latest Quarter: Q1 2026
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Liquidity Metrics | ||||||||
| Current Ratio | 1.95 | 1.88 | 1.56 | 1.52 | 1.50 | 1.47 | 2.46 | 2.82 |
| Quick Ratio | 1.64 | 1.59 | 1.38 | 1.35 | 1.32 | 1.28 | 2.12 | 2.48 |
| Solvency Metrics | ||||||||
| Debt-to-Equity | 0.47 | 0.51 | 0.94 | 1.00 | 1.14 | 1.23 | 1.31 | 1.07 |
| Debt-to-Assets | 0.21 | 0.22 | 0.34 | 0.35 | 0.38 | 0.40 | 0.41 | 0.38 |
Liquidity Assessment
Current Ratio: 1.95(Strong)
Quick Ratio: 1.64(Strong)
The company has strong liquidity with sufficient short-term assets to cover liabilities.
Solvency Assessment
Debt-to-Equity: 0.47(Low)
Debt-to-Assets: 0.21(Low)
The company maintains a balanced capital structure with manageable debt levels.
Frequently Asked Questions about DXCM
AI Answers: Common Questions About DXCM
Get AI-powered answers to the questions investors ask most about DexCom, Inc.
DexCom is not an ideal buy for short-term traders given its current downtrend and technical weakness, but for long-term investors, the stock's P/E of 26.01 and robust recurring revenue model justify its premium valuation. With strong analyst targets ($67–$115) and industry-leading margins, it remains a compelling buy on further weakness or a confirmed technical reversal.
Unless your thesis has changed or you are a short-term trader, there is no urgent reason to sell; fundamentals remain strong and long-term growth is intact. However, if you are risk-averse or need to reduce exposure due to technical breakdowns (death cross, price below all major SMAs), trimming may be prudent until a reversal is confirmed.
The biggest risks are moderating U.S. growth, regulatory and reimbursement uncertainty (especially Medicare/type 2 diabetes), and rising costs from geopolitical factors. Sentinel notes a debt-to-equity ratio of 0.51 and current ratio of 1.9, indicating manageable leverage and liquidity, but margin pressure and competitive threats remain.
Key support lies at $56.11 and $53.75, with upside resistance at $63.74, $66.11, and higher analyst targets up to $115. Most analysts see 30%+ upside from current levels if growth and product launches deliver, but a break below $54.11 could trigger further downside.
DexCom is fairly valued relative to its growth prospects, with a P/E of 26.01 and high EV/EBITDA and P/S ratios reflecting premium status in the sector. Valorem notes that while multiples have compressed, they remain justified by recurring revenue and margin expansion, but any growth slowdown could prompt further multiple contraction.
DexCom is fundamentally strong, with FY25 revenue up 15.6% YoY, EPS up 47% YoY, gross margins above 60%, and a current ratio of 1.9. Its business model is defensible with high switching costs, recurring revenue, and disciplined cost management.
Technically, DXCM is in a bearish trend below all major moving averages with a death cross in place; RSI is neutral at 44.66, and price action is weak. Watch for support at $56.11 and $53.75; a breakout above $66.11 would be needed to turn bullish in the short term.
Key catalysts include the commercial rollout and adoption of the G7 15-day CGM system, upcoming earnings, expanded insurance/Medicare coverage, and international growth. Macro events such as regulatory changes and input cost shifts could also impact the stock.
Want a Personalized Answer?
Get AI-powered insights tailored to your risk tolerance and investment goals.